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Background: Long QT syndrome (LQTS) is a cardiac ion channelopathy which presents clinically with palpitations,
syncope or sudden death. More than 700 LQTS-causing mutations have been identified in 13 genes, all of which
encode proteins involved in the execution of the cardiac action potential. The most frequently affected genes,
covering > 90% of cases, are KCNQ1, KCNH2 and SCN5A.
Methods: We describe 64 different mutations in 70 unrelated Danish families using a routine five-gene screen,
comprising KCNQ1, KCNH2 and SCN5A as well as KCNE1 and KCNE2.
Results: Twenty-two mutations were found in KCNQ1, 28 in KCNH2, 9 in SCN5A, 3 in KCNE1 and 2 in KCNE2.
Twenty-six of these have only been described in the Danish population and 18 are novel. One double heterozygote
(1.4% of families) was found. A founder mutation, p.F29L in KCNH2, was identified in 5 “unrelated” families. Disease
association, in 31.2% of cases, was based on the type of mutation identified (nonsense, insertion/deletion, frameshift
or splice-site). Functional data was available for 22.7% of the missense mutations. None of the mutations were
found in 364 Danish alleles and only three, all functionally characterised, were recorded in the Exome Variation
Server, albeit at a frequency of < 1:1000.
Conclusion: The genetic etiology of LQTS in Denmark is similar to that found in other populations. A large founder
family with p.F29L in KCNH2 was identified. In 48.4% of the mutations disease causation was based on mutation
type or functional analysis.Background
Long QT syndrome (LQTS) is a genetic disease of the
cardiac electrical system which presents clinically with
palpitations, syncope and sudden death [1,2]. To date,
more than 700 disease-causing mutations have been
found in 13 genes [1-3] and the total number of muta-
tions is probably larger [4]. All these genes are directly
or indirectly involved in the execution of the cardiac
action potential (AP) [2]. LQTS is a consequence of
a prolongation of the repolarisation phase of the AP,* Correspondence: mic@ssi.dk
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article, unless otherwise stated.caused by decreased activity of the repolarising inward
K+-currents, Iks and Ikr, or increased late activity of the out-
ward depolarising Na+-current, INa. The delayed repolarisa-
tion leads to the appearance of early after depolarisations
(EADs), due to enhancement of the Na+/Ca2+-exchan-
ger and the L-type Ca2+ channel [5]. These, together
with increased refractoriness, may trigger malignant
arrhythmias [2].
In Denmark, genetic diagnostics of LQTS has been
performed since 1996. From 2006 the management of
LQTS patients has followed national guidelines [6]. The
genetic diagnostic work is centred in five University car-
diology clinics and patients are offered a five-gene screen
of the most frequently affected genes, KCNQ1, KCNH2,ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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formed using single strand conformation polymorphism
analysis (SSCP) of the coding regions of the genes with
intronic amplification primers [7-9]. In recent years, the
mutation analysis has been performed by bi-directional
Sanger sequencing of coding regions and all previous
patients have been reanalysed. Here we report the disease-
causing mutations identified in Danish LQTS families du-
ring the preceding 15 years. Furthermore, as the evidence
base for considering mutations disease-causing is not al-
ways clear [10], and rare variants which are not associated
with disease are found in controls [11], we report our rea-
soning for considering the variants found in this cohort
disease-causing. Finally, we compare the distribution of
mutations with that found in other population studies.Methods
Patients
The patients were 70 Danish LQTS probands from unre-
lated families where mutation screening in the five LQTS
associated genes KCNQ1, KCNH2, KCNE1, KCNE2 and
SCN5A had led to the identification of a disease-causing
mutation. LQT diagnosis was based on the clinical exa-
mination of patients, which was performed according to
guidelines issued by the Danish Cardiology Society [6] by
specialists in cardiology from Danish cardiology depart-
ments at Rigshospitalet, Skejby Hospital, Aalborg Hospital,
Gentofte Hospital, Haderslev Hospital and Odense Hos-
pital. All patients had a QTC interval > 440 ms for men and
450 ms for women. All patients were Caucasian. A clinical
description of patients identified through a Danish nation-
wide survey comprising 59 families (all contributing to the
current survey) has recently been published [12].Figure 1 Location of microsatellite markers used in
haplotyping the p.F29L and p.K101E mutations in KCNH2.Mutation identification
Genomic DNA was extracted from EDTA-blood using the
commercially available Maxwell™ 16 Blood DNA purifi-
cation kit on the MaxwellR 16 System (Promega Biotech
AB, Nacka, Sweden). Genetic screening was performed by
bi-directional sequencing of PCR amplified exons with
associated flanking intronic regions. Primers sequences
are available on request. A minor proportion of muta-
tions were identified at genetic departments at Skejby
University Hospital, Rigshospitalet as well as in Norway
and the Netherlands using other, but similar, techno-
logies. All probands had the coding regions of the five
genes sequenced. All mutations were verified by sequen-
cing a second amplified amplicon. A large proportion of
patients were examined for large deletions in KCNQ1,
KCNH2, KCNE1, KCNE2 and a small part of SCN5A by
multiplex-ligation-dependent amplification (MLPA) using
the SALSA MLPA P114 kit (MRC-Holland, Amsterdam,
The Netherlands).Mutation and protein nomenclature
Mutation nomenclature uses numbering with the A of the
initiation codon ATG as +1 (www.hgvs.org/mutnomen),
based on the following RefSeqs: NM_000218.2 (KCNQ1),
NM_000238.2 (KCNH2), NM_000335.4 (SCN5A), NM_000
219.3 (KCNE1) and NM_172201.1 (KCNE2). All mutations
were checked using Mutalyzer. The protein nomenclature
was that used in the recent mutation update on LQTS [2].
Evaluation of sequence changes
Deletions, frameshift-, splice- and nonsense mutations
were considered disease-causing if not found in controls.
Concerning missense mutations, familial segregation was
ascertained if possible, but nuclear family size was in all
cases so small that it precluded a proper linkage analysis
[12]. Instead it was ascertained that the family did not
contain affected members that did not carry the family
mutation. Conservation of residues across several species
was examined. All genetic variants were evaluated in 182
randomly and anonymously collected blood donor con-
trols (364 alleles). The frequency of identified variants was
assessed using the Exome Variant Server (EVS) v.0.0.21.
(http://evs.gs.washington.edu). It was established whether
genetic variants had previously been associated with LQTS
and whether functional analysis had been performed.
The potential functional effect of changes in amino acid
composition was assessed in silico using the prediction
servers Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/)




Haplotyping was performed using the microsatellites
D7S1824, D7S1826 up-stream of KCNH2 and D7S636,
D7S3070, D7S483 and D7S1803 downstream of KCNH2
(Figure 1). CentiMorgan distances were obtained from the
Map-O-Mat database for microsatellites (http://compgen.
rutgers.edu/Mapomat/). PCR amplicons were generated
using fluorescently end-labelled primers (available at NCBI
UniSTS) at 0.4 μM per primer, per reaction. A loading mix
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Biosystems, Foster City, CA, USA) and 0.5 μl 600LIZ size
standard (Applied Biosystems) was prepared, and DNA
products were electrophoresed on an ABI PRISM® 3100
Genetic Analyser. Data were analysed using ABI Gene-
Mapper software v4.0 (Applied Biosystems).
Results
Mutation screening
The results of the mutation screening are summarized in
Tables 1, 2, 3. In the 70 families we found 64 different
mutations; 22 in KCNQ1, 28 in KCNH2, 9 in SCN5A, 3 in
KCNE1 and 2 in KCNE2. All patients were heterozygous
carriers of a single mutation, except one double heterozy-
gous proband (1.4% of families), who carried p.R583G in
KCNQ1 and p.A93T in KCNE1. Twenty-six of the muta-
tions have only been described in Danish LQTS patients
(Tables 1, 2, 3), 18 have not been reported previously.
Two mutations in KCNH2, p.F29L and p.K101E were
found in 5 and 2 unrelated families, respectively. The
MLPA analysis, applied to 65 of the probands, resulted
in the identification of a single three exon (7-9) deletion,Table 1 Mutations identified in KCNQ1
Gene cDNA Protein Mutation type Geno
KCNQ1 NM_000218 NP_000209
c.217C > A p.P73T Missense Exon
DK c.470T > G p.F157C Missense Exon
c.572-576del p.L191fs Frameshift Exon
c.592A > G p.I198V Missense Exon
c.674C > T p.S225L Missense Exon
c.667C > T p.A226V Missense Exon
c.760G > A* p.V254M Missense Exon
c.817C > T* p.L273F Missense Exon
c.905C > T p.A302V Missense Exon
c.944A > G* p.Y315C Missense Exon
c.1015-1017del p.F339del Deletion Exon
DK IVS6_IVS10del Unknown Deletion Exon
c.1017-1019del p.F340del Deletion Exon
c.1032G > A p.A344sp Splice-site IVS_0
c.1048G > A p.G350R Missense Exon
DK c.1087C > A p.H363N Missense Exon
c.1096C > T p.R366W Missense Exon
c.1202insC p.P400fs Frameshift Exon
c.1588C > T* p.Q530X Nonsense Exon
c.1747C > T* p.R583C Missense Exon
DK c.1747C > G p.R583G Missense Exon
c.1748G > A p.R583H Missense Exon
DK: Only seen in patients of Danish origin. *in vitro functional characterisation perfoIVS6_IVS10del, in KCNQ1. None of the mutations were
found in 384 control alleles.
KCNQ1 mutations
The twenty-two mutations identified in KCNQ1 seemed
evenly spread out over the gene (Table 1). Only three of
the mutations (p.F157C, IVS6_IVS10del and p.R583G)
had not previously been described in other populations.
The IVS6_IVS10del results, theoretically, either in the
excision of a considerable part of the protein rendering it
non-functional or in haploinsufficiency due to mRNA sur-
veillance mechanisms [62], and is thus considered pa-
thogenic. The remaining missense mutations all affect
highly conserved residues and many missense mutations
have been described in the S2-S3 and C-terminal regions of
the protein, respectively [2]. The p.R583G affects a codon,
where another missense mutation, p.R583C, has been
shown to have an electrophysiological phenotype similar to
that expected for a LQTS-associated mutation [42]. Among
the 18 mutations previously seen in other populations,
there were two frameshift mutations, two deletions, one
splice-site mutation and one nonsense mutation. All ofmic region Protein region Phenotype References
_01 N-term RWS [4,16]
_02 S2 RWS [17]
_03 S2-S3 RWS [4,18]
_03 S2-S3 RWS [4]
_04 S3-S4 RWS [4,19]
_04 S3-S4 RWS [4,20]
_05 S4-S5 RWS [4,20-26]
_06 S5 RWS [4,20,21,25-28]
_06 Pore RWS [4,22]
_07 Pore RWS [4,19,20,22,29-31]
_07 S6 RWS [32]
_07-Exon_9 Unknown RWS This study
_07 S6 RWS [4,20,25,33]
7 C-term RWS [4,22,25,26,34-37]
_08 C-term RWS [4,38]
_08 C-term RWS [2,26]
_08 C-term RWS [4,9,22,26,31]
_09 C-term RWS [4,20,39]
_12 C-term RWS [4,20,25,28,40,41]
_15 C-term RWS [25,42]
_15 C-term RWS This study
_15 C-term RWS [38]
rmed. RWS: Romano-Ward syndrome.
Table 2 Mutations identified in KCNH2
Gene cDNA Protein Mutation type Genomic region Protein region Phenotype References
KCNH2 NM_000238 NP_000229
DK c.65T > C p.F22S Missense Exon_01 N-term RWS This study
c.87C > A* p.F29L Missense Exon_01 N-term RWS [4,26,43]
DK c.88-90del p.I30del Deletion Exon_01 N-term RWS This study
c.221C > T p.T74M Missense Exon_02 PAS RWS [4,38]
DK c.234_241dupTGCCGCGC p.A83fs Frameshift Exon_02 PAS RWS This study
DK c.287T > C p.I96T Missense Exon_02 PAS RWS [8]
DK c.301A > G p.K101E Missense Exon_02 PAS RWS [8,44]
DK c.326T > C p.L109P Missense Exon_03 PAS RWS This study
DK c.446insC p.R148fs Frameshift Exon_03 N-term RWS This study
c.453delC p.P151fs Frameshift Exon_03 N-term RWS [45]
c.526C > T p.R176W Missense Exon_04 N-term RWS [45]
DK c.552-560del p.G184-G188del Deletion Exon_04 N-term RWS This study
c.1096C > T p.R366X Nonsense Exon_05 N-term RWS [4,8]
DK c.1199T > A p.I400N Missense Exon_06 N-term RWS [8]
c.1283C > T p.S428L Missense Exon_06 S1-S2 RWS [38]
DK c.1286delC p.S428fs Frameshift Exon_06 S1-S2 RWS [46]
DK c.1591-1671del p.R531-L539del Deletion Exon_07 S4-S5 RWS This study
c.1682C > T p.A561V Missense Exon_07 S5 RWS [4,19,25,47]
DK c.1714G > C p.G572R Missense Exon_07 S5-pore RWS [48]
c.1750G > A p.G584S Missense Exon_07 Pore RWS [25,45]
c.1862G > A p.S621N Missense Exon_07 Pore RWS [8,49,50]
c.1886A > G p.N629S Missense Exon_07 Pore RWS [4,51]
c.1898A > G p.N633S Missense Exon_07 Pore-S6 RWS [51]
DK c.2111_2114dup p.W705fs Frameshift Exon_08 C-term RWS This study
DK c.2573T > C p.I858T Missense Exon_10 C-term RWS This study
c.2738C > T p.A913V Missense Exon_12 C-term RWS [4,16]
c.2768delC p.P923fs Frameshift Exon_12 C-term RWS [52]
DK c.3090-3102del p.S1029fs Frameshift Exon_13 C-term RWS This study
DK: Only seen in patients of Danish origin. *in vitro functional characterization performed. RWS: Romano-Ward syndrome.
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to mRNA surveillance mechanisms. Of the remaining
missense mutations, four had been electrophysiologi-
cally characterized in vitro, i.e. p.V254M [21], p.L273I
[21,27,28], p.Y315C [43] and p.R583C [42]. Thus, only
four out of 15 LQTS-associated missense mutations (27%)
had established electrophysiological characteristics at the
molecular level.
KCNH2 mutations
Twenty-eight mutations were identified in KCNH2. Four-
teen of these were located in the N-terminus, and five of
these were located in the Per-Arnt-Sim domain. Five were
located in the C-terminus, only five mutations were
located in the pore-region (Table 2). This is surprising,
as the majority of previously identified LQTS associatedmutations in KCNH2 have been located in the pore region
[2]. Fifteen of the mutations have only been described
in the Danish population. Eight of the Danish specific
mutations were deletions, or frameshift mutations. The
remaining eight Danish-specific mutations were missense
mutations and all involved conserved amino acid residues.
Among the mutations found in other populations, two
were frameshift mutations, one was nonsense and 10 were
missense mutations. Only one of these missense muta-
tions, p.F29L, had been demonstrated to have an in vitro
electrophysiological effect compatible with LQTS [43], so
the remainder were considered disease-associated based
on the evolutionary conservation of the involved amino
acid residue and the absence of the mutation among 364
control alleles as well as a previously reported association
with LQTS. The observation of the association of these
Table 3 Mutations identified in SCN5A, KCNE1 or KCNE2
Gene cDNA Protein Mutation type Genomic region Protein region Phenotype References
SCN5A NM_000335 NP_000326
DK c.611+ 1G > A Intronic splice Splice-site IVS5 D1-S3 RWS This study
DK c.955C > A p.G319S Missense Exon_08 D1-S5-S6 RWS [7]
c.1018C > T p.R340W Missense Exon_09 D1-S5-S6 RWS [4]
DK c.1141-3C > A Intronic splice Splice-site IVS9 D1-S6 RWS This study
c.1231G > A p.V411M Missense Exon_10 D1-S6 RWS [4,16]
c.4783T > A p.F1595I Missense Exon_27 DIV-S3 RWS [4]
DK c.4786G > A p.V1596M Missense Exon_27 DIV-S3 RWS This study
DK c.5354T > A* p.L1785Q Missense Exon_28 C-term RWS This study
c.6013C > G* p.P2005A Missense Exon_28 C-term RWS [53]
KCNE1 NM_000219 NP_000210
DK c.179G > A p.G60D Missense Exon_03 TM RWS This study
c.226G > A* p.D76N Missense Exon_03 Cyto RWS [4,25,52,54-56]
DK c.277G > A p.A93T Missense Exon_03 Cyto RWS This study
KCNE2 NM_172201 NP_751951
c.170T > C* p.I57T Missense Exon_02 TM RWS [4,57-61]
c.193G > A* p.V65M Missense Exon_02 TM RWS [59]
DK: Only seen in patients of Danish origin. *in vitro functional characterization performed. RWS: Romano-Ward syndrome.
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rates their role in the causation of LQTS. Finally, a large
number of mutations in the regions affected by the muta-
tions described here, have been associated with LQTS [2].
All the remaining missense mutations in KCNH2, ex-
cept p.A913V, were conserved to the level of zebrafish.
The p.A913V mutation changed an alanine into a valine,
where the valine was found at the same codon in rodents.
However, the mutation had previously been associated
with LQTS [16] and in the absence of deviations from
familial disease segregation, and the absence of other mu-
tations in the five genes as well as of the mutation in 364
control alleles, it was considered disease-causing.
SCN5A mutations
Nine mutations were identified in SCN5A (Table 3), five
of which have only been described in the Danish popula-
tion. Four mutations have not been reported before. Two
mutations were intronic splice-site mutations and the
remaining mutations were missense mutations located in
the DI, DIV and C-terminal regions. This distribution
is compatible with the one found when accumulating
all known SCN5A LQTS-associated mutations [2]. The
splice-site mutations were considered disease-causing be-
cause they are believed to result in aberrant mRNA spli-
cing resulting in the synthesis of SCN5A ion channels
with prolonged depolarisation contributing to delayed
repolarisation. The splice mutations most likely do not re-
sult in haploinsufficiency as this would most likely give a
Brugada syndrome phenotype [63]. One of the missensemutations, p.P2005A, has previously been associated with
sudden infant death syndrome and shown to result in late
persistent INa current, compatible with LQTS [53]. An
in vitro electrophysiological analysis of the functional con-
sequence of the p.L1785Q mutation has shown that it re-
sults in increased late persistent INa current, but also in a
reduction of the total INa (Kanters et al., submitted), sug-
gesting that the electrophysiological phenotype may be a
combination of Brugada syndrome and LQTS, as pre-
viously described for SCN5A mutations [63], e.g. the
p.E1784K mutation [64]. The remaining missense muta-
tions interfere with conserved residues and have not been
found in controls; further the mutations p.F1596I and
p.V1597M, are located in the C-terminal part of SCN5A,
where mutations causing LQTS are particularly frequent
[2]. The rare polymorphism p.D1819N, known to be asso-
ciated with increased QT-interval in normal individuals
[65], was found in a single p.F29L family and not con-
sidered pathogenic, despite being previously reported as
associated with LQTS [57] The C-terminally located mu-
tations are likely to interfere with fast inactivation of the
INa current [66]. Likewise, the remaining missense muta-
tions, p.G319S, p.R340W and p.V411M, are located in the
DI-S5-S6 region, a region with a high frequency of LQTS-
associated mutations [2].
KCNE1 mutations
Three mutations were found in KCNE1, two of which,
p.G60D and p.A93T, have only been found in the Danish
population and have not been reported before. The p.
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an isolated proband, where family data were not attain-
able. The p.G60D and p.D76N interfered with amino acid
residues conserved in human, rat, mouse, cow and frog,
whereas the alanine at residue 93 was only conserved in
mouse, rat, cow and human. However, the N-terminus of
frog minK is not conserved at all from amino acid residue
85 – 105 in the human sequence (corresponding to resi-
due 80 – 95 in the frog minK sequence). However,
the missense mutations p. Y81C, p.W87R, p.R98W, and
p.P127T – as well as p.D76N, located in the cytoplasmic
C-terminus of minK, have previously been associated with
LQTS [2].
KCNE2 mutations
Two mutations were found, p.I57T and p.V65M, both
previously described in other populations as associated
with LQTS [57,58] and shown to interfere with Kv7.1
function [59] in a way compatible with an association
with LQTS. Both interfered with highly conserved resi-
dues and were not found in 384 control alleles.
Disease causation
The association between a mutation and disease is of para-
mount importance when the mutation findings are used for
cascade screening and clinical management as is the case in
Denmark [12]. This is a particular problem when family
data are not sufficient to establish linkage. As none of the
mutations are present in the 364 control alleles and all but
three (SCN5A:p.P2005A, KCNE1:p.D76N and KCNE2:
p.I57T) were absent from the EVS, moreover, the three va-
riants reported here occurred at frequencies < 1:1000, it is
therefore unlikely that the variants reported here are poly-
morphisms. Frame-shift, splice-site- nonsense- or indel
mutations represents 31.2% of the mutations identified in
this cohort (Tables 1, 2, 3). Such mutations have a direct
effect on the integrity of the polypeptide chain and are
considered explanatory for LQTS. However, the remaining
68.8% are missense mutations, that need to be differen-
tiated from the naturally occurring functionally insignifi-
cant non-synonymous variants in the same proteins. A
classical method of supporting disease causality in LQTS
is electrophysiological examination of mutated channel
proteins to disclose a reduction in repolarising K+- current
(KCNQ1, KCNH2, KCNE1, KCNE2) or late persistence of
depolarising Na+- current (SCN5A) [2]. Such information,
however, was only available for 22.7% of the missense mu-
tations (Tables 1, 2, 3).
We used the prediction servers Polyphen-2, SIFT and
Mutation Assessor to assess the significance of all the
missense mutations for interference with protein function.
The results are given in Table 4. As expected the majority
of mutations where an electrophysiological assessment
was available (p.V254M, p.L273F, p.Y315C, p.R583C inKCNQ1, p.F29L in KCNH2, p.L1785Q in SCN5A, p.D76N
in KCNE1, p.I57T and p.V65M in KCNE2) were found
to have an effect on protein function. One mutation,
p.P2005A in SCN5A was not found to be disruptive of
protein function, despite having been determined to cause
functional impairment by in vitro electrophysiological as-
sessment. This suggests that the sensitivity of these predic-
tion servers is reasonable. The remaining, not functionally
characterised, missense mutations, with the exception of
KCNQ1 - p.P73T, p.R583G, p.R583H; KCNH2:p.A913V
and KCNE1:p.A93T, were all found to be at least possibly
disruptive of protein function.
The founder mutations in KCNH2
Two of the missense mutations, p.F29L [43] and p.K101E
[44], were found in five and two “unrelated” families, re-
spectively. Haplotype analysis, using six polymorphic
microsatellite markers, spanning 24.6 cM, flanking the
KCNH2 gene at distances ranging from 10.1 Mb 3’ to
2.9 Mb 5’ as shown in Figure 1, demonstrated that both
mutations were founder mutations (Additional file 1:
Table S1).
Population distribution of mutations
The distribution of Danish LQTS mutations is compared
with four other large mutation surveys comprising verified
LQTS patients in Table 5. The proportion of KCNQ1 mu-
tations seems to be lower in Danish patients, 34.3%, than
in other populations, where the proportion of KCNQ1
mutations ranged from 39.4% - 48.6%. This trend was not
significant, however, using a Chi-Square test. The propor-
tion of KCNH2 mutations in Denmark is within the range
seen in the other populations, whereas the proportion of
patients with mutations in the three rarely affected genes,
SCN5A, KCNE1 and KCNE2 is considerably higher, 23.7%,
than seen in the other populations (range: 10.7% - 16.2%).
The distribution of mutation types does not seem to differ
substantially between the populations. Likewise, the
frequency of compound heterozygosity was similar in
the populations where it was established. In a Norwegian
study no compound heterozygotes were convincingly de-
monstrated, but 18 cases of Jervell and Lange-Nielsen syn-
drome had been found [67].
Discussion
We have identified 64 different mutations in 70 Danish
LQTS families referred for five-gene screening. This is by
far the highest number of different mutations identified
per capita in any country and it amounts to approximately
1: 72.000 inhabitants. The signature of the genetics of
LQTS in Denmark is that of many “private” mutations
(Tables 1, 2, 3). With respect to this considerable inter-
allelic and inter-genic variation, the Danish mutation
spectrum is similar to that found in other populations
Table 4 In silico functional analysis of missense variants
Gene Protein Polyphen-2 SIFT Mutation assessor
KCNQ1 p.P73T 0 0 0
KCNQ1 p.F157C 0 1 2
KCNQ1 p.I198V 1 1 1
KCNQ1 p.S225L 1 1 1
KCNQ1 p.A226V 2 1 2
KCNQ1 p.V254M 2 1 2
KCNQ1 p.L273F 2 1 2
KCNQ1 p.A302V 2 1 2
KCNQ1 p.Y315C 2 1 3
KCNQ1 p.G350R 2 1 2
KCNQ1 p.H363N 1 1 2
KCNQ1 p.R366W 2 1 2
KCNQ1 p.R583C 1 0 1
KCNQ1 p.R583G 0 0 1
KCNQ1 p.R583H 0 0 1
KCNH2 p.F22S 2 0 2
KCNH2 p.F29L 0 1 2
KCNH2 p.T74M 2 1 2
KCNH2 p.I96T 1 1 2
KCNH2 p.K101E 0 1 3
KCNH2 p.L109P 1 0 2
KCNH2 p.R176W 2 1 0
KCNH2 p.I400N 2 1 2
KCNH2 p.S428L 0 0 2
KCNH2 p.A561V 2 1 2
KCNH2 p.G572R 2 1 2
KCNH2 p.G584S 1 0 0
KCNH2 p.S621N 1 1 3
KCNH2 p.N629S 2 1 2
KCNH2 p.N633S 1 0 1
KCNH2 p.I858T 1 1 2
KCNH2 p.A913V 0 0 0
SCN5A p.G319S 0 0 2
SCN5A p.R340W 1 1 0
SCN5A p.V411M 2 1 3
SCN5A p.F1595I 0 0 2
SCN5A p.V1596M 1 1 2
SCN5A p.L1785Q 2 1 3
SCN5A p.P2005A 0 0 0
KCNE1 p.G60D 2 1 2
KCNE1 p.D76N 1 0 2
Table 4 In silico functional analysis of missense variants
(Continued)
KCNE1 p.A93T 0 0 1
KCNE2 p.I57T 2 1 1
KCNE2 p.V65M 2 1 1
Polyphen-2 scores: 0: benign, 1 possibly damaging for function; 2: Probably
damaging for function. SIFT scores: 0: Tolerated and 1: Not tolerated, Mutation
Assessor scores; 0-1: no functional effect, 2-3: functional effect on
protein function.
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nificant, that the proportion of mutations in KCNQ1 is
reduced and the proportion of mutations in SCN5A,
KCNE1 and KCNE2 correspondingly increased in the
Danish LQTS patients. The same tendency is registered
when comparing the Danish mutation spectrum to a col-
lection of mutations identified in the five genes in persons
referred for LQT testing, but where no knowledge on the
clinical phenotype was available [4]. The relatively high
frequency of mutations in the more rarely affected genes
stresses the need of performing a five-gene screen when es-
tablishing the etiology of individual Danish LQTS families.
The patients described here were studied and collected
over a long span of years, from 1996 – 2010. In this period
the clinical picture of LQTS was better defined, the possi-
bility of referral for genetic analysis increased and the indi-
cation for genetic analysis in LQTS cases was established
in 2006 [6]. Furthermore, detailed clinical information was
variable in quality, therefore it can not be excluded that, in
some cases, other factors, e.g. structural heart disease or
mixed phenotypes, might not have been identified and
taken into account. Consequently, it is very difficult to es-
tablish a success rate for the genetic screening across this
period. But it is probably comparable to the 70% reported
from Norway in a much smaller collection of mutations
[67]. Likewise, we cannot really state anything about the
cost-effectiveness of including more genes in the basic
screen or the suitability or cost-effectiveness of MLPA
analysis of the five genes. A large proportion of cases,
65/70 had MLPA analysis performed in order to detect
larger insertion/deletion mutations and a single case with
a three exon deletion in KCNQ1 was identified. However,
considering the relatively low cost of MLPA analysis and
the possibility to detect deletions that would have escaped
classical Sanger sequencing, our data suggests that MLPA
analysis – or more extensive methods for detection of
minor structural abnormalities - should be part of the five
gene screen as the frequency of deletions (1.4%) is com-
parable to that of KCNE mutations.
In general, disease causation was based on the identifi-
cation of a mutation that; either resulted in a deletion or
a frameshift, introduced a stop codon or disrupted cor-
rect splicing. In the case of missense mutations, the mu-
tation should involve the exchange of a conserved amino
Table 5 Distribution of mutations and mutation types in this study and four other large studies
This study Berge et al [67] Napolitano et al [38] Tester et al [16] Splawski et al [25]
Number of mutations 64 37 233 211 177
KCNQ1 (%) 34.3 42.6 48.6 41.7 39.4
KCNH2 (%) 43.8 46.3 38.8 42.2 51.5
SCN5A (%) 14.1 9.3 10.1 15.2 6.1
KCNE1 (%) 4.7 1.9 1.7 0.5 2.3
KCNE2 (%) 3.1 0.0 0.7 0.5 2.3
Mutation type
Missense (%) 68.8 64.9 72.0 75.0 72.3
Nonsense (%) 3.1 13.5 5.1 5.7 6.2
Deletion (%) 9.4 2.7 14.1 2.5 5.0
Frameshift (%) 14.1 13.5 6.1 11.4 9.6
Splice site (%) 4.7 5.4 2.7 4.3 6.7
Compound heterozygotes (%)* 1.4 0 3.9 5.4 n.a.
*Percentage of families.
Christiansen et al. BMC Medical Genetics 2014, 15:31 Page 8 of 11
http://www.biomedcentral.com/1471-2350/15/31acid and not be present in > 100 control alleles. If the
mutation had previously been associated with LQTS this
strengthened the argument for disease-causation. Func-
tional assessment was not available for novel mutations.
However, a large proportion, 48.4%, of mutations were
classified as disease-causing as a consequence of the mu-
tation type or the results of functional in vitro assessment.
None of the mutations were present in Danish controls
and three were found at very low frequencies in the EVS.
The remaining missense mutations all, with five excep-
tions, were positive for disrupting protein function in one
or several prediction servers. The prediction servers had
a reasonable sensitivity, 9/10 functionally characterised
mutations were correctly classified, but detailed analyses
on larger datasets are necessary to establish specificity.
Despite the promising performance of protein function
interference prediction servers it will still be of great sig-
nificance to be able to perform a functional analysis of
identified novel variants.
Interestingly, this study and a subsequent survey of
the cardiology clinics revealed that Andersen syndrome,
despite being originally described in Denmark [68], as
well as Jervell and Lange-Nielsen syndrome and Tim-
othy syndrome patients, are not found in Danish cardi-
ology clinics (Kanters, pers.com.).
The identification of a large KCNH2 p.F29L founder
family, comprising 7.1% of Danish LQTS families, is in-
teresting, and the location of the family in the Northern
part of Jutland, where it constitutes ca. 50% of affected
families makes it easier to genotype patients from this part
of Denmark. The p.F29L mutation has previously been
found in North America [43] in a family of Northern
European origin (Splawski, pers. com.). The mutation has
been found to have an electrophysiological effect in vitro
compatible with LQTS [43].Each LQTS family has to be carefully examined as there
is a risk of compound heterozygosity or digenic inhe-
ritance. Our data suggest that this risk is similar to that re-
ported in other countries (Table 5). The clarification of
the individual significance of either mutation in a family
with a compound heterozygous index patient requires cas-
cade screening to be performed and identification of car-
riers of the single mutations. In our experience this is
rarely possible due to the small size of families [12].
The translation of molecular findings in LQTS patients
into patient-specific clinical management decisions is diffi-
cult due to the low level of strict evidence, the complexity
of the genetics, including the existence of genetic mo-
difiers of phenotype [10]. Some of these problems may be
alleviated if the use of patient-specific pluripotent stem
cells turns out to give relevant information [69]. However,
until such new approaches become routine, it is, with
reference to the large role played by the use of previously
reported information on disease-causation, important that
all mutation findings and clinical as well as molecular
follow-up of mutations are made available to the larger
scientific community.
Conclusions
The Danish spectrum of LQTS causing mutations is very
similar to that of the rest of the world, even though the
frequency of KCNQ1 mutations seems relatively reduced
and the proportion of mutations in rarely affected genes
increased. There was a considerable proportion of novel
mutations identified, but they were distributed on the
genes largely as seen elsewhere. Despite a shortage of
functional information and a long collection period nearly
all mutations identified were reasonably classified as
causative. The identification of a large founder family with
p.F29L in KCNH2 may become of importance for local
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http://www.biomedcentral.com/1471-2350/15/31patient management as well as studies into the prevention
of sudden cardiac death in LQT2. Sharing of genotype
and phenotype data as well as development of improved
in silico predictions of functional consequences of muta-
tions will improve the management of LQTS.
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